Genetic Information
Gene & Transcript Details
| ID | Status | Details |
|---|---|---|
| NM_000051.3 | RefSeq Select | 13147 nt | 386–9556 |
| NM_000051.4 | MANE Select | 12915 nt | 151–9321 |
Variant Details
Clinical & Population Data
Population Frequency
gnomADClinVar
OpenThe c.4397_4398delGAinsCG pathogenic mutation (also known as p.R1466P), located in coding exon 28 of the ATM gene, results from an in-frame deletion of GA and insertion of CG at nucleotide positions 4397 to 4398. This results in the substitution of the arginine residue for a proline residue at codon 1466, an amino acid with dissimilar properties. This variant has been detected in trans with a pathogenic mutation in ATM in an individual with a clinical diagnosis of ataxia-telangiectasia (A-T) (Ambry internal data). In addition, an alteration resulting in the same protein change, c.4397G>C, has been identified in conjunction with a pathogenic ATM mutation in a cohort of individuals from the UK diagnosed with A-T (Jackson TJ et al. Dev Med Child Neurol. 2016 07;58:690-7). This alteration is located in the HEAT domain of the ATM protein and based on internal structural assessment, it is more disruptive than nearby known pathogenic variants (Drozdetskiy A et al. Nucleic Acids Res. 2015 Jul;43:W389-94; Perry J et al. Cell. 2003 Jan;112:151-5; Ambry internal data). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis and is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
This sequence change replaces arginine, which is basic and polar, with proline, which is neutral and non-polar, at codon 1466 of the ATM protein (p.Arg1466Pro). Information on the frequency of this variant in the gnomAD database is not available, as this variant may be reported differently in the database. This missense change has been observed in individual(s) with ataxia-telangiectasia (PMID: 26896183). ClinVar contains an entry for this variant (Variation ID: 254753). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
"This variant has been reported in ClinVar as Uncertain significance (4 clinical laboratories) and as Pathogenic (1 clinical laboratories) and as Likely pathogenic (1 clinical laboratories) and as Uncertain Significance by ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Variant Curation Expert Panel, ClinGen expert panel."
COSMIC Somatic Evidence
Open
Functional Impact & Domains
Functional Domain
Error in OpenAI Consolidation. OncoKB: ATMR1466PATMR1466PSomaticNCBI Gene:472|Show additional gene information Variant OverviewATM, a kinase involved in the DNA damage response, is mutated in various solid and hematologic malignancies.There is no available functional data about the ATM R1466P mutation (last reviewed on 03/24/2023). However, it has been identified as a statistically significant hotspot and is likely to be oncogenic. JAX-CKB: ATM R1466P does not lie within any known functional domains of the Atm protein (UniProt.org). R1466P fails to rescue survival and proliferation of ATM-haploid cells upon olaparib treatment in a high-throughput cell culture assay (PMID: 40580951), and therefore, is predicted to lead to a loss of Atm protein function.
Click on previews to view full database entries. External databases may require institutional access.
Computational Analysis
Pathogenicity Predictions
SpliceAISpliceAI Scores
Window: ±500bp| Effect Type | Score | Position |
|---|---|---|
| Acceptor Loss (AL) | 0.0 | -160 bp |
| Donor Loss (DL) | 0.0 | 39 bp |
| Acceptor Gain (AG) | 0.0 | -187 bp |
| Donor Gain (DG) | 0.01 | -130 bp |
VCEP Guidelines
Applied ACMG/AMP Criteria (VCEP Specific)
PS3 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)
PM2 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)
PP5 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)
BP4 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)